<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080820</url>
  </required_header>
  <id_info>
    <org_study_id>CMX157-101/A01</org_study_id>
    <nct_id>NCT01080820</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of CMX157 in Healthy Adult Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chimerix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chimerix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of CMX157 and the amount
      of CMX157 that reaches the blood stream, the manner in which the body processes CMX157 and
      the time that it takes to eliminate CMX157 following one oral dose when given to healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs), absolute values and changes over time of clinical chemistry including troponin, hematology, and urinalysis, vital signs (blood pressure (BP) and heart rate), electrocardiogram</measure>
    <time_frame>dosing-28 days post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CMX157 PK parameters: AUC(0-âˆž), AUC(0-t), Cmax, C12, and C24 following single dose administration.</measure>
    <time_frame>dosin - 28 days post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo + Viread</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Viread</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CMX157 + Viread</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CMX157</intervention_name>
    <description>One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.</description>
    <arm_group_label>CMX157 + Viread</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.</description>
    <arm_group_label>Placebo + Viread</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viread</intervention_name>
    <description>One single oral dose of 300mg Viread.</description>
    <arm_group_label>Placebo + Viread</arm_group_label>
    <arm_group_label>Viread</arm_group_label>
    <arm_group_label>CMX157 + Viread</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Males or females of non-childbearing potential, 18 to 55 years of age. Males must be
        able and willing to use adequate contraceptive methods throughout the study.

        Exclusion Criteria:

          1. Currently nursing females, pregnant females, or females of child-bearing potential.

          2. Hypersensitivity to tenofovir.

          3. Use of any antiviral, corticosteroid, immunosuppressive, or anticoagulant prescription
             drug within 4 weeks prior to enrollment. Use of any other prescription drug within 14
             days prior to enrollment.

          4. Use of any over-the-counter medication, herbal/nutraceutical preparation, within 7
             days prior to enrollment.

          5. Administration of any potentially nephrotoxic drug within 14 days prior to enrollment.

          6. Use of an investigational drug and/or treatment within 30 days prior to enrollment.

          7. Use of illicit drugs within 6 months prior to screening and enrollment, based on
             history and a urine drug screen.

          8. Infection with HIV, HBV or HCV.

          9. History of abuse of alcohol or other substance (s) within 6 months prior to
             enrollment.

         10. History or symptoms of cardiovascular disease, including but not limited to coronary
             artery disease, hypertension, congestive heart disease, cardiomyopathy, and cardiac
             conduction disorders.

         11. History of clinically significant hypotension (including orthostatic), fainting, or
             lightheadedness.

         12. History of gastrointestinal disease or impairment.

         13. History of renal impairment or disorder.

         14. History of liver disease or impairment.

         15. History of cancer, except basal cell carcinoma.

         16. History of pathologic bone fractures; history or risk of osteopenia

         17. History of diabetes, metabolic disease, or autoimmune disease; history of
             immunodeficiency in healthy volunteers.

         18. Acute illness or fever 38 C within 1 week prior to enrollment.

         19. Supine blood pressure - systolic outside the range of 90-140 mmHg, or diastolic
             outside the range of 50-90 mmHg.

         20. Resting heart rate &gt; 100 or &lt; 45 beats per minute.

         21. Body Mass Index (BMI) &gt;31 or &lt;18, or body weight &lt;50 kg for men and &lt; 45 kg for women.

         22. Whole blood donation within 56 days or plasma donation within 30 days prior to
             enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Flach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2010</study_first_submitted>
  <study_first_submitted_qc>March 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2010</study_first_posted>
  <last_update_submitted>June 30, 2011</last_update_submitted>
  <last_update_submitted_qc>June 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Margaret Anderson, Clinical Development Manager</name_title>
    <organization>Chimerix, Inc</organization>
  </responsible_party>
  <keyword>Healthy adult volunteers</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

